Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: Potential implication in relation to the pathogenesis of Parkinson's disease

Journal of Neurochemistry

Volumn 74, Issue 4, 2000, Pages 1605-1612

  Soto Otero, Ramón ^a   Méndez Álvarez, Estefanía ^a   Hermida Ameijeiras, Álvaro ^a   Muñoz Patiño, Ana María ^b   Labandeira Garcia, José Luis ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

6 Hydroxydopamine; Antioxidants; Autoxidation; Neurotoxicity; Oxidative stress; Parkinson's disease

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; CYSTEINE; GLUTATHIONE; HYDROGEN PEROXIDE; NEUROTOXIN; OXIDOPAMINE; OXYGEN; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SCAVENGER; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOOXIDATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TOXICOKINETICS;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; CYSTEINE; FEMALE; FREE RADICAL SCAVENGERS; GLUTATHIONE; HYDROGEN PEROXIDE; NEURONS; OXIDATION-REDUCTION; OXIDOPAMINE; OXYGEN CONSUMPTION; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHOLYTICS;

ANIMALIA;

EID: 0342369569     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0741605.x     Document Type: Article

References (44)

1. Andrew R., Watson D. G., Best S. A., Midgley J. M., Wenlong H., and Petty R. K. H. (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 18, 1175-1177.
2. Ben-Shachar D., Eshel G., Finberg J. P. M., and Youdim M. B. H. (1991) The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441-1444.
3. Breese C. R. and Breese G. R. (1998) The use of neurotoxins to lesion catecholamine-containing neurons to model clinical disorders, in Highly Selective Neurotoxins: Basic and Clinical Applications (Kostrzewa R. M., ed), pp. 19-73. Humana Press, Totowa, New Jersey.
4. Cadet J. L., Katz M., Jackson-Lewis V., and Fahn S. (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 476, 10-15.
5. Carstam R., Brinck C., Hindemith-Augustsson A., Rorsman H., and Rosengren E. (1991) The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta 1097, 152-160.
6. Clark J. B. (1993) Electrochemical assay, in Enzyme Assay: A Practical Approach (Eisenthal R. and Danson M. J., eds), pp. 181-190. IRL Press, Oxford.
7. Cohen G., Heikkila R. E., Allis B., Cabbat F., Demblec D., MacNamee D., Mytilineou C., and Inston B. (1976) Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. J. Pharmacol. Exp. Ther. 199, 336-352.
8. Curtius H. C., Wolhensberger M., Steinmann B., and Redweik S. (1974) Mass fragmentography of dopamine and 6-OH-dopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J. Chromatogr. 99, 529-540.
9. Enochs W. S., Sarna T., Zecca L., Riley P. A., and Swartz H. M. (1994) The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J. Neural Transm. 7, 83-100.
10. Eyer P. (1991) Effects of superoxide dismutase on the autoxidation of 1,2-hydroquinone. Chem. Biol. Interact. 80, 159-176.
11. Fornstedt B., Rosengren E., and Carlsson A. (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25, 451-454.
12. Gee P. and Davison A. J. (1989) Intermediates in the aerobic autoxidation of 6-hydroxydopamine: relative importance under different reaction conditions. Free Radic. Biol. Med. 6, 271-284.
13. Glinka Y. Y. and Youdim M. B. H. (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292, 329-332.
14. Glinka Y., Tipton K. F., and Youdim M. B. H. (1996) Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J. Neurochem. 66, 2004-2010.
15. Glinka Y., Gassen M., and Youdim M. B. H. (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural Transm. 50, 55-66.
16. Glinka Y., Tipton K. F., and Youdim M. B. H. (1998) Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur. J. Pharmacol. 351, 121-129.
17. Graham D. G., Tiffany S. M., Bell W. R. Jr., and Gutknecht W. F. (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
18. Heikkila R. and Cohen G. (1972) Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine. Mol. Pharmacol. 8, 241-248.
19. Ichitani I., Okamura H., Matsumoto Y., Nagatsu I., and Ibata Y. (1991) Degeneration of the nigral dopamine neurons after 6-hydroxydopamine injection into the rat striatum. Brain Res. 549, 330-353.
20. Irwin I. and Langston J. W. (1995) Endogenous toxins as potential etiologic agents in Parkinson's disease, in Etiology of Parkinson's Disease (Ellenberg J. H., Koller W. C., and Langston J. W., eds), pp. 153-201. Marcel Dekker, New York.
21. Jellinger K., Linert L., Kienzl E., Herlinger E., and Youdim M. B. H. (1995) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural Transm. 46, 297-314.
22. Jonsson G. and Sachs C. (1970) Effects of 6-hydroxydopamine on the uptake and storage of noradrenaline in sympathetic adrenergic neurons. Eur. J. Pharmacol. 9, 141-155.
23. Kumar R., Agarwal A. K., and Seth P. K. (1995) Free radical-generated neurotoxicity of 6-hydroxydopamine. J. Neurochem. 64, 1703-1707.
24. Liang Y.-O., Wightman R. M., and Adams R. N. (1976) Competitive oxidation of 6-hydroxydopamine by oxygen and hydrogen peroxide. Eur. J. Pharmacol. 36, 455-458.
25. Liang Y.-O., Plotsky P. M., and Adams R. N. (1977) Isolation and identification of an in vivo reaction product of 6-hydroxydopamine. J. Med. Chem. 20, 581-583.
26. 3H-6-hydroxydopamine in adrenergic nerves. Experientia 27, 297-299.
27. Meister A., Tate S. S., and Griffith O. W. (1981) γ-Glutamyl transpeptidase. Methods Enzymol. 77, 237-253.
28. Méndez-Álvarez E., Soto-Otero R., Sánchez-Sellero I., and López-Rivadulla Lamas M. (1998) In vitro inhibition of catalase activity by cigarette smoke: relevance for oxidative stress. J. Appl. Toxicol. 18, 443-448.
29. Nappi A. J. and Vass E. (1994) The effects of glutathione and ascorbic acid on the oxidation of 6-hydroxydopa and 6-hydroxydopamine. Biochim. Biophys. Acta 1201, 498-504.
30. O'Brien P. J. (1991) Molecular mechanisms of quinone cytotoxicity. Chem. Biol. Interact. 80, 1-41.
31. Odh G., Carstam R., Paulson J., Wittbjer A., Rosengren E., and Rorsman H. (1994) Neuromelanin of the human substantia nigra: a mixed-type melanin. J. Neurochem. 62, 2030-2036.
32. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Levis V., Donaldson D., and Togasaki D. M. (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67, 631-647.
33. Roginsky V. A., Barsukova T. K., Bruchelt G., and Stegmann H. B. (1997) The oxidation of catecholamines and 6-hydroxydopamine by molecular oxygen: effect of ascorbate. Z. Naturforsch. 52c, 380-390.
34. Sachs C., Jonsson G., Heikkila R., and Cohen G. (1975) Control of the neurotoxicity of 6-hydroxydopamine by intraneuronal noradrenaline in rat iris. Acta Physiol. Scand. 93, 345-351.
35. Sagara J., Miura K., and Bannai S. (1993) Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61, 1672-1676.
36. Sauer H. and Oertel W. H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401-415.
37. Senoh S., Creveling C. R., Udenfriend S., and Witkop B. (1959) Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine. J. Am. Chem. Soc. 81, 6236-6240.
38. Shen X.-M., Zhang F., and Dryhurst G. (1997) Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. Chem. Res. Toxicol. 10, 147-155.
39. Sian J., Dexter D. T., Lees A. J., Daniel S., Jenner P., and Marsden C. D. (1994) Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36, 356-361.
40. Spencer J. P. E., Jenner P., Daniel S. E., Lees A. J., Marsden D. C., and Halliwell B. (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71, 2112-2122.
41. Sullivan S. G. and Stern A. (1981) Effects of superoxide dismutase and catalase on catalysis of 6-hydroxydopamine and 6-aminodopamine autoxidation by iron and ascorbate. Biochem. Pharmacol. 30, 2279-2285.
42. Ungerstedt U. (1968) 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5, 107-110.
43. Yamada K., Umegaki H., Maezawa I., Iguchi A., Kameyama T., and Nabeshima T. (1997) Possible involvement of catalase in the protective effect of interleukin-6 against 6-hydroxydopamine toxicity in PC12 cells. Brain Res. Bull. 43, 573-577.
44. Zhang F. and Dryhurst G. (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J. Med. Chem. 37, 1084-1098.